We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
Sign in
Sign in
Companies → HCW Biologics Inc.
Save to list
Remove

HCW Biologics Inc.

United States, Miramar
Report a bug?
Claim ownership and edit
Description
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Industries
SIC
Address:

2929 North Commerce Parkway

Website:
Revenue
Recent news:

Market Activity Highlights: Biotech, Tech, and Energy Lead Trading Volume

Recent market data shows concentrated trading activity driving price movements in biotech, major technology, energy, and cryptocurrency-linked assets across U.S. exchanges.

Source: IndexBox Mar 16, 2026

XNAS - Delayed Quote - USD
HCWB
0.74 -0.01 (-1.86%)
At close March 23 03:28 UTC
Candle
Line
1D
5D
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 06/22/2025
Market Cap: 9.75 M
Enterprise Value: 22.58 M
Trailing P/E: N/A
Forward P/E: -8.31
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 3.30
Price/Book (mrq): -0.60
Enterprise Value/Revenue: 15.63
Enterprise Value/EBITDA: -0.79
Financial Highlights
Profitability and Income Statement
Profit Margin: N/A%
Return on Assets (ttm): -57.20%
Return on Equity (ttm): -27.73 K%
Revenue (ttm): 1.45 M
Net Income Avi to Common (ttm): -24.75 M
Diluted EPS (ttm): -24.80
Balance Sheet and Cash Flow
Total Cash (mrq): 1.11 M
Total Debt/Equity (mrq): N/A%
Levered Free Cash Flow (ttm): -5.67 M
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.